BRIEF-Editas Medicine And Genevant Sciences To Collaborate To Develop Novel Mrna-Lnp Gene Editing Therapeutics

Reuters
22 Oct 2024

Oct 21 (Reuters) - Editas Medicine Inc :

* EDITAS MEDICINE AND GENEVANT SCIENCES TO COLLABORATE TO DEVELOP NOVEL MRNA-LNP GENE EDITING THERAPEUTICS

* TO COMBINE CRISPR CAS12A WITH GENEVANT'S LNP TECHNOLOGY

* GENEVANT ELIGIBLE FOR UP TO $238 MILLION IN PAYMENTS

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10